Phil Grayeski

Phil Grayeski is an accomplished professional in the venture capital and biotechnology sectors, currently serving as a Partner at KdT Ventures since April 2018, where responsibilities include serving as a Board Observer for companies such as Radar Therapeutics and Tacit Therapeutics. In addition to this role, Phil holds multiple board member positions for various firms, including Cirsium Biosciences and Perceptive Technologies. Phil co-founded Transcera Inc. and has previous experience as a Strategy Advisor for Ribometrix. Academic qualifications include a Doctor of Philosophy in Genetics from the University of North Carolina at Chapel Hill, a Master of Philosophy in Bioscience Enterprise from the University of Cambridge, and a Bachelor of Science in Genetics and Chemistry from The University of Georgia.